Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
about
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsProfound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infectionAssessment of ultrasound for use in detecting lipoatrophy in HIV-infected patients taking combination antiretroviral therapy.The role of aldosteronism in causing obesity-related cardiovascular risk.Increased aldosterone among HIV-infected women with visceral fat accumulationIncreasing Obesity in Treated Female HIV Patients from Sub-Saharan Africa: Potential Causes and Possible Targets for Intervention.Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.HIV-associated lipodystrophy: impact of antiretroviral therapy.Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study.Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls.Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings.Thymidine analogues suppress autophagy and adipogenesis in cultured adipocytes.Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.Association between weight gain and clinical outcomes among malnourished adults initiating antiretroviral therapy in Lusaka, Zambia.Multiple frequency bioimpedance is an adequate tool to assess total and regional fat mass in HIV-positive patients but not to diagnose HIV-associated lipoatrophy: a pilot studyImprovement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitutionNutrition and the HIV-associated lipodystrophy syndrome.The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection.Does persistent HIV replication explain continued lymphoma incidence in the era of effective antiretroviral therapy?Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.Cohort profile: the Swiss HIV Cohort study.High-density Hyaluronic Acid for the Treatment of HIV-related Facial LipoatrophyFrom lipodystrophy to cardiovascular disease: new insight into the management of HIV infection
P2860
Q28088839-808DC0DE-A5A8-4FF3-86B0-9CFF5FB4FDC6Q28748901-646BC70E-1AE7-47A2-A4DF-B90C63A05868Q33797575-CD0BEAA2-9E0F-441C-B463-E8079673B17FQ33995992-BC8367B0-B580-441B-BDD6-A64C95396EAAQ34066641-A06D7CF9-5A9B-4BC5-BDB1-49F625E8D092Q34502149-F6F07E4E-8DB1-4CDD-94C7-4602E1BAB57CQ34637395-FDAB0402-6294-4B79-9399-1A184B7DCBBEQ34655845-93067047-1AE1-4BDB-A9D6-733F03A768F9Q34802246-78EED800-8E17-4EB1-BF64-4B11B6A49617Q35898696-BD963D6C-1C71-42CA-90FE-F3DE94DC9E5DQ35913712-2D940594-9BC9-4904-9D5B-C8F729373B9BQ36068146-4FF71C40-4FD0-4D09-88A8-8419579E0FD1Q36077885-B30AFEDB-E512-4034-AC26-A304D0FCFC6CQ36505451-9BF38E0C-F8A4-4D49-BED7-3439581DF2BDQ36903976-9F22B902-8DE0-460E-8829-DAC95C775D73Q37111867-AB284AD5-A407-45C7-9C6B-1CF4BF74E53AQ37419698-2884A95F-6B15-4E21-A5D1-2AB417EA59A6Q37423288-65B3B4A4-B416-41BD-97B7-83FA11F84575Q38061798-DC3C8174-F5F6-4923-B0E5-C922176E0878Q38421020-46EBBD16-2126-4687-A3B7-E9222CB1655AQ38963668-80B2A076-EABD-49B6-9D85-D4E76EDEC401Q39123448-09B25D68-403F-4892-8E5E-C9B8871227F3Q40100018-6F67FE38-9690-48D8-9629-63AF434C7FCFQ40613036-E1F9F1D7-3108-4EDB-8B74-4B5F61A42B84Q41756147-E842C35F-DAFF-47F4-BAB1-0A8EF1CC648DQ46959264-EBE8B7E9-482D-4EA9-B2BD-E805B660CAB4Q58797959-BC95B57C-67F3-4265-9B33-8248AB041F47Q58798012-1F3539C7-D7E9-4704-A392-A2A684642806
P2860
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
@ast
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
@en
type
label
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
@ast
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
@en
prefLabel
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
@ast
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
@en
P2093
P2860
P1433
P1476
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.
@en
P2093
B Hirschel
E Bernasconi
J-M Evison
T Perneger
V Schiffer
P2860
P304
P356
10.1111/J.1468-1293.2007.00537.X
P577
2008-01-22T00:00:00Z